Munich-based deepc, a medtech firm, introduced on Tuesday, March 28, that it has secured €12M in a Sequence A spherical of funding led by Sofinnova Companions with participation from Bertelsmann Investments and Profitable Mindset Ventures.
The German firm says it is going to use the funds to develop new options and increase the commercialisation of deepcOS, its proprietary working system that powers AI integration inside radiology workflows.
The proceeds will even assist increase the corporate’s geographic protection and to develop further options inside deepcOS.
As part of the funding spherical, Simon Turner, Associate at Sofinnova Companions, will be a part of the corporate’s Board of Administrators.
A digital drugs pioneer
Based by Dr. Franz Pfister, Julia Moosbauer, Paul Mayer, and Dr. Michael Meyerhoff, deepc is on a mission to offer radiology groups with entry to one of the best regulator-approved AI diagnostic instruments.
The corporate’s cloud-native, vendor-neutral platform deepcOS integrates seamlessly with current radiology workflows, providing authorized third-party AI distributors an environment friendly approach to commercialise their options.
It additionally offers hospitals and clinics a safe, “one-stop-shop” for his or her AI-assisted radiology wants.
“At deepc, we consider that AI has the ability to revolutionise the way in which we method healthcare,” says Dr. Franz Pfister, co-founder and CEO of deepc.
“Our AI platform, deepcOS, is a sport changer for radiology, permitting for quicker, extra correct diagnoses and finally bettering affected person outcomes. We’re thrilled to welcome Sofinnova Companions and Bertelsmann Investments on board,” says Pfister.
Based mostly out of Paris, London, and Milan, Sofinnova Companions is a enterprise capital agency in life sciences, specialising in healthcare and sustainability.
The VC has backed over 500 corporations and has over €2.5B below administration.
“Our funding in deepc underscores our conviction that Digital Drugs holds huge promise and that enabling applied sciences will probably be on the forefront of the digital revolution in healthcare, exactly the main target of our Digital Drugs funding technique,” says Simon Turner, Associate at Sofinnova Companions.
“deepcOS permits extensive adoption of AI into a significant a part of the affected person journey. The crew has demonstrated the profit that they’ll present to healthcare professionals and sufferers,” provides Turner.